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Introduction: Endothelial nitric oxide synthase (eNOS), the enzyme in charge 
of nitric oxide production, plays a crucial role in vascular biology. However, 
the impact of single nucleotide polymorphisms (SNPs) affecting the gene 
encoding for eNOS (eNOS) on coronary artery diseases remains under debate 
and no data were available at present in populations originating from 
Mahghreb. 
Aim of the Study: Our purpose was to evaluate the association between the 
eNOS -786T/C and +894G/T SNPs and (i) the risk of myocardial infarction 
(MI) and (ii) variations in systolic (SBP) and diastolic (DBP) blood pressure 
values. 
Patients and Methods: Concerning MI, the SNPs were characterised in a case-
control study (70 cases vs 68 controls) based on the male population originating 
from Oran, Algeria. 
Results: The associations with blood pressure values were assessed in an 
enlarged control group including 115 male subjects. Since the -786T/C 
SNP could not be associated to MI, the genotype distribution of the 
+894G/T genotypes signifi cantly differed between MI cases and controls 
(p=0.025). The risk of MI (odds ratio) associated to the +894G/T SNP was 
estimated to 1.2 (95%CI=[1.03;1.32]). The haplotype analysis confi rmed 
this association and the absence of impact of the -786T/C SNP. On the other 
hand, no consistent association was shown between the two SNPs and SBP or 
DBP. 
Conclusion: As observed in other populations, the eNOS +894G/T SNP 
was associated with MI in the Algerian population but the mechanism 
underlying the effect could not be related to variations in blood pressure.




Endothelial nitric oxide synthase, myo-
cardial infarction, blood pressure, ge-
netic epidemiology.
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INTRODUCTION                                          
Despite major advances in prevention 
and treatments, coronary artery disease 
(CAD) remains the major cause of mor-
tality and morbidity in developed coun-
tries1. In Northern Africa, epidemiolog-
ical data are poorly documented despite 
a lately reported impressive prevalence 
of CAD in these populations2. Athero-
sclerosis, the underlying cause of CAD, 
is partly heritable although the involved 
genes and the associated relative risks 
remain largely under debate3. Numerous 
studies support that decreased nitric ox-
ide (NO) production related to endothe-
lial dysfunction plays a crucial role in 
the initiation and progression of athero-
genesis and the presence of endothelial 
dysfunction can predict the presence of 
CAD and provides prognostic informa-
tion4. NO plays a key role in the relaxa-
tion of vascular smooth muscle cells 
(VSMC), reduces VSMC migration and 
proliferation, inhibits adhesion of plate-
lets and leukocytes to the endothelium, 
and limits the oxidation of low-density 
lipoproteins, all these mechanisms be-
ing strongly involved in the atherogenic 
process5. Moreover, as a potent vasodi-
latator, NO is deeply engaged in the 
regulation of blood pressure.
In vascular endothelium, NO is con-
stitutively produced from L-arginine 
by endothelial nitric oxide synthase 
(eNOS)6. It has been shown that eNOS 
inhibition accelerates atherosclerosis in 
animal models and that abnormalities in 
the endothelial NO pathway is present 
in atherosclerotic patients7,8. Moreo-
ver, numerous epidemiological studies 
pointed out short nucleotide polymor-
phisms (SNPs) within the eNOS gene 
(eNOS) as putative risk factors for 
CAD, but the results are often confl ict-
ing and data from populations originat-
ing from Maghreb are scattered. There-
fore, in a case-control study carried in 
the Algerian population of Oran, we 
evaluated the impact of the -786T/C 
and the +894G/T SNPs, respectively 
located in the 5’-fl ancking region and 
in exon 7 of eNOS, on the risk of myo-
cardial infarction (MI) and on systolic 
(SBP) and diastolic (DBP) blood pres-
sure values. 
PATIENTS AND METHODS                              
Study population:
The study population was composed 
of subjects aged 25 to 64 years, living 
in Oran (Algeria) and whose parents 
and grand-parents were born in the 
west of the country. The case group 
was composed of 68 subjects who had 
survived a MI defi ned on the basis of 
the multinational monitoring of trends 
and determinants of cardiovascular dis-
ease (MONICA) criteria9,10. Controls 
(n=115) were randomly selected from 
the Algerian National Census list of 
households. Anthropometric measure-
ments, clinical and biological examina-
tions, as well as prevalence of risk fac-
tors were systematically recorded. SBP 
and DBP were measured twice, with 
an interval of at least 5 min, in a sitting 
position, after resting for at least 5-10 
min. Genomic DNA was extracted from 
peripheral blood leukocytes.
Analysis of the eNOS -786T/C and 
+894G/T SNPs:
For the -786T/C SNP, the forward 
and reverse primers were 5’-CCCAT-
CACACAAAAC-3’ and 5’-CTCAAT-
ACACAAACTAC-3’. The genotypes 
were deduced after an incubation 
step with the restriction endonucle-
ase HpaII (New England Biolabs). 
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For the + 894G/T SNP, the forward 
and reverse primers used were 5’-
GCTCCAGGGGCACCTCAA-3’ and 
5’GCATTCAGCACGGCTGGA3’ re-
spectively. The genotypes were deduced 
by using the BanII restriction enzyme 
(New England Biolabs).
Statistical analyses:
For case-control comparison, 68 out 
of 115 controls were selected in order 
to approximately match the age dis-
tribution of controls (54.3±8.0 years) 
to that of the cases (56.1±8.5 years). 
Genotype distributions between cases 
and controls were compared using the 
Pearson’s chi-square test. The associa-
tions of the eNOS SNPs with the risk of 
MI were assessed by multiple logistic 
regression analysis. SBP and DBP were 
compared between genotypes by anal-
ysis of covariance that used a general 
linear model. The tests were adjusted 
for age, body mass index, diabetes, 
current smoking and alcohol consump-
tion. These analyses were carried out 
with the SAS release V.8.2 software. 
Due to their closely location within the 
eNOS gene, we calculated the linkage 
disequilibrium (LD) between the two 
SNPs and we tested the impact of the 
various eNOS haplotypes on the risk of 
MI and on SBP and DBP by using a sto-
chastic-EM algorithm implemented in 
RESULTS                                                    
The comparisons of the eNOS -786T/C 
and +894G/T genotype distributions 
between cases of myocardial infarction 
and controls are presented in (Table 1). 
Both eNOS -786T/C and +894G/T gen-
otype distributions fulfi lled the Hardy-
Weinberg equilibrium. 
The eNOS -786T/C genotype distri-
bution did not differ between cases 
and controls. Consistently, the risk of 
MI associated to the polymorphism, 
which was estimated to be 1.4 (95% 
CI=[0.86;2.38]), did not reach statisti-
cal signifi cance after adjustment for 
covariates (OR[95%CI]=1.38 [0.80; 
2.39]). Conversely, the distribution 
of the eNOS +894G/T SNP is statisti-
cally different between cases and con-
trols (p=0.025). Subjects carrying the 
eNOS+894T allele, especially homozy-
gotes, are more frequent in cases than 
in controls. The risk of MI associated 
to+894T allele was estimated to be 
closed to 1.2 (95%CI=[1.03; 1.32]), re-
maining unchanged after adjustment for 
covariates.
the THESIAS software (freely availa-
ble from http://www.genecanvas.org)11. 
p<0.05 was considered as statistically 
signifi cant.
Table 1: Comparison of eNOS -786T/C and +894G/T genotype distributions between cases 
(n=68) and controls (n=68).
N (%) -786T/C +894G/T
Cases Controls Cases Controls
TT 22 (32.3) 28 (41.2) GG 30 (42.9) 41 (60.3)
TC 34 (50.0) 33 (48.5) GT 28 (40.0) 24 (35.3)
CC 12 (17.7)  7 (10.3) TT 12 (17.1) 3 (4.4)
p=0.359 p=0.025
92
Endothelial nitric oxide synthase gene polymorphisms and risk of MI
Although being closely located within 
the eNOS gene, the LD between the 
two SNPs was unexpectedly weak 
(D’=0.038; r²=0.097). However, we 
compared the distribution of the eNOS 
haplotypes between cases of MI and 
controls (Table 2). Data showed that, 
compared to the most frequent haplo-
type (-786T*+894G), the haplotypes 
carrying the +894T allele were consis-
tently more frequent in cases than in 
controls. The risk of MI associated to 
the -786C*+894T haplotype was sig-
nifi cantly two fold increased; the risk 
associated to the -786T* + 894T allele 
was comparable even if it did not reach 
statistical signifi cance, probably due to 
the lack of power related to the low fre-
quency of that haplotype.
Haplotypes Cases % Controls % Crude OR [95%CI]    Adjusted* OR [95%CI]
-786T*+894G 0.45 0.56 - -
-786C*+894T 0.23 0.13 2.3 [1.1;4.7]; p=0.018 2.2 [0.9;4.9]; p=0.038
-786C*+894G 0.19 0.22 0.9 [0.5;1.6]; p=0.613 0.8 [0.4;1.6]; p=0.584
-786T*+894T 0.13 0.09 1.7 [0.7;4.3]; p=0.204 2.2 [0.7;6.4]; p=0.132
* Tests adjusted for age, BMI, diabetes, current smoking and alcohol consumption.
Table 2: Comparison of eNOS haplotype distribution between cases (n=68) and controls 
(n=68).
The comparisons of SBP and DBP be-
tween subgroups of eNOS -786T/C 
and +894G/T genotypes are presented 
in Table 3. The -786T/C SNP was only 
slightly associated with a decreased 
DBP. The +894G/T was not associated 
with any variation in SBP and DBP. 
The comparison of SBP and DBP be-
tween subGroups of eNOS -786T/C 
and +894G/T haplotypes in 115 control 
subjects confi rmed that none of the two 
SNPs could be associated with SBP or 
DBP (data not shown). 
DISCUSSION                                                     
The present study investigated the im-
pact of eNOS SNPs on myocardial in-
farction and on blood pressure values 
in a male sample of the Algerian popu-
lation. This is the fi rst report in which 
eNOS polymorphisms were analysed in 
a Northern African population. To date, 
the prevalence of eNOS polymorphisms 
has been established for Caucasian, Af-
rican American, Hispanic, Korean and 
Japanese populations. 
The frequency of the rare -786C allele in 
our population was 34.6%. The highest 
frequency was reported in Caucasians 
(38%)12 and the allele is less common 
in Korean (8,6%)13, Japanese (9,2%)14, 
and African Americans (17,5%)15. The 
allele frequencies of the + 894G/T SNP 
was also determined by ethnicity. In the 
present study, the prevalence of the al-
lele was 22,1%. The + 894T allele was 
found to be more frequent in Hispan-
ics (30%)16 and Caucasians (29%)17, 
but less frequent in African Americans 
(15,5%)15, Indians (12%)18 and Japanese 
(9%)14. These fi ndings further support 
the important role of ethnicity in deter-
mining the prevalence of genetic poly-
morphisms an their subsequent putative 
impacts in a given population. 
Our data suggest that the -786T/C SNP 
cannot be associated with the risk of 
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MI, a result that was also obtained in 
many Caucasian populations19 as well 
as in the population of Taiwan20. Con-
versely, we associated the rare allele 
of the + 894G/T polymorphism with 
a moderate but increased risk of MI. 
This result is in agreement with others 
obtained in many countries, from both 
Caucasian21,22 and Japanese23,24 origins 
but the present fi ndings contrast with 
those obtained from the French subset 
of the ECTIM (Etude Cas-Temoins de 
l’Infarctus du Myocarde) study25, the 
authors pointing out an increased risk 
of MI in individuals carrying the +894G 
allele. At the protein level, the +894G/T 
SNP encodes for the replacement of the 
Glu298 by a residue of Asp (Glu298-
Asp). Interestingly, numerous studies 
have suggested that the risk for CAD 
would be confi ned to homozygous in-
dividuals for the + 894T allele, sug-
gesting that homozygosity for Asp298 
should produce a signifi cant decrease 
in the amount of eNOS or in its enzy-
matic activity22,26. Compared with the 
eNOS Glu298 protein, it has been also 
recently shown that the eNOS Asp298 
protein has enhanced susceptibility to 
intracellular proteolytic cleavage26,27. 
Other possible explanations for the as-
sociation of the + 894G/T SNP with the 
risk of MI rely on putative linkage dis-
equilibrium between the mutation and 
another still unknown functional poly-
morphism located in the eNOS locus or 
in another gene nearby.
Conversely, in spite of the crucial role of 
eNOS in NO production and the func-
tion of NO in the regulation of blood 
pressure, no effect of eNOS SNPs on 
SBP and DBP could be shown. Consist-
ently, it as been recently reported that 
plasma NO level and blood pressure 
were not associated in different geno-
types of -786T/C and + 894G/T SNP in 
African Americans.28
CONCLUSION                                                
Our data, although being obtained from 
a low effective study, suggested that 
the + 894G/T would be an independ-
ent genetic marker of MI in the Alge-
rian population. Therefore, further stud-
ies are needed to investigate whether 
the + 894G/T of the eNOS gene could 
represent useful genetic markers for 
identifying individuals at risk for devel-
opment of CAD. Moreover, it is neces-
sary to explore and clarify the putative 
effects of the eNOS + 894G/T SNP on 
endothelial NO function.
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